|
|
|
Volumn 6, Issue 4, 2004, Pages 443-450
|
|
Technology evaluation: ChimeriVax-DEN, Acambis/Aventis
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CHIMERIVAX DEN;
DENGUE VACCINE;
RECOMBINANT VACCINE;
YELLOW FEVER VACCINE;
ARTICLE;
CLINICAL TRIAL;
DENGUE;
DENGUE VIRUS;
DISEASE MODEL;
DRUG EFFICACY;
DRUG FORMULATION;
DRUG METABOLISM;
DRUG SAFETY;
DRUG SYNTHESIS;
DRUG TOLERABILITY;
HUMAN;
IMMUNE SYSTEM;
IMMUNIZATION;
IMMUNOGENICITY;
IN VITRO STUDY;
IN VIVO STUDY;
INFECTION PREVENTION;
NONHUMAN;
SIDE EFFECT;
SINGLE DRUG DOSE;
STRUCTURE ACTIVITY RELATION;
TOXICITY TESTING;
VIREMIA;
VIRUS REPLICATION;
ANIMALS;
ANTIBODIES, VIRAL;
CHILD;
CLINICAL TRIALS, PHASE I;
DENGUE;
DENGUE HEMORRHAGIC FEVER;
DENGUE VIRUS;
DRUG EVALUATION, PRECLINICAL;
HUMANS;
VACCINES, SYNTHETIC;
VIRAL VACCINES;
WEST NILE VIRUS VACCINES;
DENGUE VIRUS;
|
|
EID: 4444360536
PISSN: 14648431
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (6)
|
|
References (0)
|
